Previous close | 32.22 |
Open | 32.87 |
Bid | 26.00 x 800 |
Ask | 34.13 x 800 |
Day's range | 32.33 - 34.48 |
52-week range | 27.36 - 79.45 |
Volume | |
Avg. volume | 692,488 |
Market cap | 2.011B |
Beta (5Y monthly) | 1.65 |
PE ratio (TTM) | 3.09 |
EPS (TTM) | 11.06 |
Earnings date | 02 May 2022 - 06 May 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 60.14 |
CAMBRIDGE, Mass., May 04, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will give a presentation at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 8:00am PT (11:00am ET) in Las Vegas, Nev.
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 0.96% and 66.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass., May 03, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2022.